恒瑞医药：HRS-4642注射液等多款药物获得临床试验批准

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries, including Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for several drugs [1] - The approved drugs include HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, Adebali monoclonal antibody injection, Bevacizumab injection, SHR-A2102 for injection, Appleseed Famitinib capsules, and Hydroxyethyl sulfonic acid Darsilil tablets [1] - A specific trial will focus on the safety, tolerability, and efficacy of HRS-4642 in combination with anti-tumor drugs in solid tumor subjects, categorized as a Phase I/II study [1]